Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Sofregen Medical Acquires SERI® Surgical Scaffold Product Line from Allergan

Sofregen Medical Inc.
Posted on: 11 Nov 16

Sofregen Medical Inc., an innovative company committed to advancing silk-based medical technologies to address soft tissue defects, today announced the acquisition of the SERI® Surgical Scaffold product line from Allergan plc. Polaris Partners and other founding investors provided financing for the transaction. Terms of the deal were not disclosed.

The acquisition strategically aligns with Sofregen’s vision of advancing a variety of silk-based solutions to treat patients with soft-tissue defects. SERI®, which is currently utilized for soft tissue support in plastic and reconstructive surgical procedures, is the only silk-based surgical mesh approved for soft tissue support and repair. Through bio replacement, SERI® facilitates neovascularization and native tissue generation over time, providing lasting support and strength. Seri® has been successfully used in over 10,000 surgical procedures requiring surgical mesh. Sofregen also has a pipeline of novel, injectable, silk-based products currently under development.

Howard Weisman, Chairman of Sofregen Medical Inc., expressed his enthusiasm for the promise of this pioneering technology:

“Silk has proven to promote regeneration of the body’s own tissue, allowing for tremendous potential to effectively repair both disfiguring injuries and delicate defects,” said Weisman. “The global market for products to address soft-tissue aesthetics is estimated to reach $5 billion next year. We are excited to be adding the SERI® product line to our platform, and look forward to continuing to help surgeons who are eager to restore confidence and improve the quality of life for patients around the world.”

Chris White, Sofregen’s incoming President and Chief Operating Officer, described organizational expansion plans to support SERI® in the marketplace:

“As the new supplier of SERI® Surgical Scaffold, Sofregen is committed to meeting the needs of customers without disruption,” said White. “We are bolstering our commercial organization, adding field-based sales representatives and medical affairs personnel to support the SERI® product line with outstanding service. We look forward to connecting with customers as we continue to innovate and grow.”

For additional information about SERI® products and services, please visit www.seri.com.

About Sofregen Medical, Inc.

Sofregen Medical is a pioneer in the use of silk, nature’s healing fiber, in a variety of forms to help physicians address soft tissue defects, giving patients a fresh start, restoring confidence, and improving quality of life. From our Seri® surgical mesh to innovative products under development, Sofregen is committed to restoring function and cosmetic appearance for medical and aesthetic patients worldwide. For more information, please visit www.sofregenmedical.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161111005130/en/

Business Wire
www.businesswire.com

Last updated on: 11/11/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.